CoPARC: Colorado Pulmonary Alcohol Research Collaborative

CoPARC：科罗拉多州肺酒精研究合作组织

• 批准号: 9926794
• 负责人: ELLEN L BURNHAM
• 金额: $ 70.15万
• 依托单位: UNIVERSITY OF COLORADO DENVER
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-08-01 至 2023-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9926794
• 关键词: Acetaldehyde; Acetylcarnitine; Admission activity; Adult Respiratory Distress Syndrome; Alcohol consumption; Alcohols; Aliquot; Alveolar Macrophages; Area; Biocompatible Materials; Blood; Blood specimen; Bronchoalveolar Lavage Fluid; Bronchoscopy; Burn injury; California; Cannabis; Cells; Chicago; Clinical; Collection; Colorado; Communication; Communities; Critical Illness; Data; Data Set; Development; Economic Burden; Emerging Technologies; Endotoxins; Enrollment; Ensure; Epithelial Cells; Equipment and supply inventories; Erythrocytes; Evaluation; Exhalation; Faculty; Fatty Acids; Fostering; Funding; Generations; Genomics; Geography; Goals; Grant; Growth; Health; Histologic; Host Defense; Host Defense Mechanism; Human; Immune system; Immunity; Immunoglobulins; Inflammatory; Infrastructure; Institution; Intensive Care Units; Knowledge; Lipids; Louisiana; Lung; Lung diseases; Malondialdehyde; Marketing; Mechanical ventilation; Medical center; Mission; Monoclonal Antibody R24; Morbidity - disease rate; Nasal Epithelium; National Heart, Lung, and Blood Institute; National Institute on Alcohol Abuse and Alcoholism; Nebraska; Needs Assessment; Online Systems; Oropharyngeal; Outcome; Oxidative Stress; Pathology; Patient-Focused Outcomes; Patients; Peripheral Blood Mononuclear Cell; Phospholipids; Plasma; Pneumonia; Production; Proteins; Publications; Recording of previous events; Research; Research Personnel; Research Subjects; Resources; Respiratory Failure; Respiratory System; Risk; Risk Factors; San Francisco; Site; Smoker; Specimen; Strategic Planning; Streptococcus pneumoniae; System; Targeted Research; Taxonomy; Therapeutic Intervention; Time; Tissues; Translational Research; Universities; Urine; adduct; airway epithelium; alcohol effect; alcohol research; alcohol use disorder; antimicrobial peptide; base; biomarker development; burden of illness; career development; clinical material; cytokine; data sharing; genome sequencing; improved; innovation; lung microbiome; marijuana use; microbiome alteration; microbiota; mortality; novel; pathogen; prevent; prophylactic; racial diversity; receptor expression; response; whole genome

Project Summary The goal of this proposal is to seek continued support to augment and sustain an established Alcohol Research Resource, known as CoPARC (Colorado Pulmonary-Alcohol Research Collaborative). CoPARC's mission is to facilitate research that will prevent the development of alcohol-associated pneumonia, ameliorate its deleterious complications, and ultimately improve clinical outcomes. Alcohol use disorders (AUDs) confer an eight-fold increased risk for community-acquired pneumonia. AUDs also increase morbidity for patients with pneumonia, including increasing the risk of respiratory failure necessitating intensive care unit (ICU) admission and mechanical ventilation. Further, AUD-associated pneumonia is frequently complicated by the development of the acute respiratory distress syndrome (ARDS). Centered at the University of Colorado Denver (UCD) and led by Ellen L. Burnham, MD, MS, the CoPARC infrastructure has enabled enrollment of over 370 ambulatory subjects with and without AUDs, and 237 critically ill patients with pneumonia or burn injury, established ARDS risk factors that are more prevalent in patients with AUDs. Resource materials have originated from institutions with a history of NIAAA-funded translational research in alcohol-related pulmonary diseases, including UCD, Emory University (EU), and Loyola University Chicago (LUC); and from the University of California San Francisco (UCSF) with NHLBI support. Presently, thousands of biospecimens have been collected, including bronchoalveolar lavage (BAL) fluid and cell aliquots; bronchial brushings; and blood specimens. To date, 26 investigators from 11 external institutions have utilized over 6100 biospecimens from 92% of the enrolled subjects. For the renewal, 4 sites (EU, LUC, UCSF, and the University of Nebraska Medical Center) and UCD will collect materials for CoPARC. A Steering Committee comprised of investigators from UCD, EU, LUC, Louisiana State University, UNMC, and Thomas Jefferson University will provide rigorous oversight for CoPARC, including prioritization of biospecimen distribution, and ensuring that milestones promoting use of the Resource are achieved. Innovations that are planned include collection of novel specimens such as whole lung explants; expertise in high-throughput genomics applications; access to administrative data sets enriched in patients with alcohol use; and organization of clinical, inventory, and experimental data to foster cross- investigator sharing. Aims for the renewal are in line with the NIAAA's strategic plan to identify mechanisms of alcohol action and alcohol-related pathology to more fully understand how alcohol asserts its effects on human health. They include: 1) expand and diversify clinical and biological materials obtained from ambulatory subjects with AUDs and critically ill patients, along with appropriate controls, 2) engage emerging web-based systems to prioritize data and biospecimen sharing, and streamline communications between investigators as well as the Steering Committee and 3) enhance visibility and marketing to promote the distribution, growth, and sustainability of the Resource.

项目摘要 该提案的目标是寻求持续的支持，以扩大和维持一个已建立的酒精 研究资源，被称为CoPARC（科罗拉多肺酒精研究协作）。CoPARC的 使命是促进研究，以防止酒精相关性肺炎的发展，改善 其有害的并发症，并最终改善临床结果。酒精使用障碍（AUDs） 患社区获得性肺炎的风险增加八倍AUD还增加了患有以下疾病的患者的发病率： 肺炎，包括增加呼吸衰竭的风险，需要入住重症监护室（ICU） 和机械通气此外，AUD相关性肺炎经常因以下发展而复杂化： 急性呼吸窘迫综合征（ARDS）以科罗拉多丹佛大学（UCD）为中心， 由Ellen L. Burnham，MD，MS，CoPARC基础设施已经招募了370多名门诊患者， 有和没有AUDs的受试者，以及237例肺炎或烧伤危重患者，建立了ARDS 在AUD患者中更常见的风险因素。资源材料来源于机构 具有NIAAA资助的酒精相关肺部疾病转化研究的历史，包括UCD， 埃默里大学（欧盟）和洛约拉大学芝加哥（LUC）;以及来自加州圣 弗朗西斯科（UCSF）与NHLBI支持。目前，已收集了数千份生物标本，包括 支气管肺泡灌洗液（BAL）和细胞等分试样;支气管刷拭;和血液标本。迄今为止， 来自11个外部机构的研究者使用了92%入组患者的6100多份生物标本 科目对于更新，4个研究中心（EU，LUC，UCSF和内布拉斯加大学医学中心）和UCD 将为CoPARC收集材料。指导委员会由来自UCD，欧盟，lucc， 路易斯安那州立大学、联合国大学和托马斯杰斐逊大学将对以下方面进行严格监督： CoPARC，包括生物标本分配的优先次序，并确保促进使用 资源已经实现。计划的创新包括收集新的标本，如全肺 外植体;高通量基因组学应用方面的专门知识;获得丰富的管理数据集， 酒精使用的患者;组织临床，库存和实验数据，以促进交叉- 调查员分享更新的目的符合NIAAA的战略计划，以确定 酒精的作用和酒精相关的病理学，以更充分地了解酒精如何断言其对人类的影响， 健康它们包括：1）扩大和多样化从门诊获得的临床和生物材料 AUD受试者和重症患者，沿着适当的对照，2）参与新兴的基于网络的 优先考虑数据和生物标本共享的系统，并简化研究者之间的沟通， 以及指导委员会，3）提高知名度和营销，以促进分销，增长， 资源的可持续性。